Serum uric acid is a predictive biomarker of incident metabolic syndrome at the Brazilian longitudinal study of adult Health (ELSA-Brasil)

Imagem de Miniatura
Arquivos
art_DINIZ_Serum_uric_acid_is_a_predictive_biomarker_of_2022.PDF (445.21 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
DINIZ, Maria de Fatima Haueisen Sander
BELEIGOLI, Alline M. R.
GALVA, Aline Isabel Rodrigues
TELLES, Rosa Weiss
SCHMIDT, Maria Ines
DUNCAN, Bruce B.
RIBEIRO, Antonio Luiz P.
VIDIGAL, Pedro G.
BARRETO, Sandhi Maria
Citação
DIABETES RESEARCH AND CLINICAL PRACTICE, v.191, article ID 110046, 7p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aim: To investigate whether serum uric acid (SUA) levels and hyperuricemia can be predictive biomarkers of incident metabolic syndrome(MS) among different body mass index(BMI) categories, and to investigate SUA cutoffs that best discriminate individuals with incident MS. Methods: We analyzed 7,789 participants without MS at baseline of ELSA-Brasil study. Logistic regression models were performed to evaluate associations between incident MS and SUA levels/hyperuricemia, expressed by odds ratios(ORs) and confidence intervals(95 % CI). Results: We found 1,646 incident MS cases after a median follow-up of 3.8[3.5-4.1] years. Incident MS was present among 8.3 % (n = 290) of participants with normal weight, 28.3 % (n = 850) with overweight, 39.8 % (n = 506) with obesity. Among incident MS participants of total sample, 33.0 % had hyperuricemia [SUA > 6.0 mg/dL (356.9 mu mol/L)]. After all adjustments, SUA was independently prognostic of incident MS: for each 1 mg/ dL increase in SUA the odds of incident MS were 45 % higher (OR1.45[CI95 %1.34-1.55 p <.01]). Associations were found for those presenting normal weight, overweight and obesity (OR1.43[CI95 %1.31-1.57 p <.01; OR1.22[CI95 %1.13-1.32 p <.01]; and OR1.16[CI95 %1.04-1.29 p <.05]) respectively. Hyperuricemia was independently associated with incident MS (OR1.88[CI95 %1.49-0.2.36 p <.01]). The SUA cut point level maximizing sensitivity and specificity in the discrimination of incident MS was 5.0 mg/dL. Conclusions: SUA level is an independent predictive biomarker of incident MS at all BMI categories.
Palavras-chave
Uric acid, Hyperuricemia, Metabolic syndrome, Incidence study, Biomarker, Cohort
URI
https://observatorio.fm.usp.br/handle/OPI/50421
Referências
  1. Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
  2. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  3. Bardin T, 2014, CURR OPIN RHEUMATOL, V26, P186, DOI 10.1097/BOR.0000000000000028
  4. Billiet Laura, 2014, ISRN Rheumatol, V2014, P852954, DOI 10.1155/2014/852954
  5. Molina MDB, 2013, REV NUTR, V26, P167, DOI 10.1590/S1415-52732013000200005
  6. Borghi C, 2020, EUR J INTERN MED, V80, P1, DOI 10.1016/j.ejim.2020.07.006
  7. Borghi C, 2018, CARDIOL J, V25, P545, DOI 10.5603/CJ.2018.0116
  8. Chen WY, 2022, ENDOCRINE, V76, P62, DOI 10.1007/s12020-022-02979-z
  9. Cicero AFG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29955-w
  10. da Silva MT, 2020, PUBLIC HEALTH NUTR, V23, P506, DOI 10.1017/S1368980019002490
  11. DeBosch BJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5642
  12. Eckel N, 2015, METABOLISM, V64, P862, DOI 10.1016/j.metabol.2015.03.009
  13. Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
  14. Fini MA, 2014, AM J MED, V127, pE18, DOI 10.1016/j.amjmed.2014.02.031
  15. Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
  16. Diniz MDHS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004010
  17. Johnson RJ, 2018, AM J KIDNEY DIS, V71, P851, DOI 10.1053/j.ajkd.2017.12.009
  18. Johnson RJ, 2013, DIABETES, V62, P3307, DOI 10.2337/db12-1814
  19. Katsiki N, 2021, CURR PHARM DESIGN, V27, P1941, DOI 10.2174/1381612827666210104124320
  20. Kim Y, 2016, DIABETIC MED, V33, P428, DOI 10.1111/dme.12970
  21. Krishnan E, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000157
  22. Li L, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/3175418
  23. Li LJ, 2020, AM J TRANSL RES, V12, P3167
  24. Li RR, 2018, ASIA PAC J CLIN NUTR, V27, P1344, DOI 10.6133/apjcn.201811_27(6).0022
  25. Liu ZT, 2015, SCI REP-UK, V5, DOI 10.1038/srep14325
  26. Maiuolo J, 2016, INT J CARDIOL, V213, P8, DOI 10.1016/j.ijcard.2015.08.109
  27. Masulli M, 2022, NUTR METAB CARDIOVAS, V32, P1245, DOI 10.1016/j.numecd.2022.01.028
  28. Molina Maria del Carmen Bisi, 2013, Cad. Saúde Pública, V29, P379, DOI [10.1590/S0102-311X2013000200024, 10.1590/S0102-311X2013000600024]
  29. Norvik JV, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0265-8
  30. Oda E, 2014, HEART VESSELS, V29, P496, DOI 10.1007/s00380-013-0386-2
  31. Pugliese NR, 2021, CLIN RES CARDIOL, V110, P1073, DOI 10.1007/s00392-021-01815-0
  32. Roberson LL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-14
  33. Saklayen MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0812-z
  34. Sluijs I, 2015, DIABETES, V64, P3028, DOI 10.2337/db14-0742
  35. Tikhonoff V, 2022, J HUM HYPERTENS, V36, P976, DOI 10.1038/s41371-021-00613-5
  36. van Smeden M, 2021, J CLIN EPIDEMIOL, V132, P142, DOI 10.1016/j.jclinepi.2021.01.009
  37. Virdis A, 2020, HYPERTENSION, V75, P302, DOI 10.1161/HYPERTENSIONAHA.119.13643
  38. Wong JC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245436
  39. Zhang CW, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110795
  40. Zhang SS, 2019, CURR PHARM DESIGN, V25, P700, DOI 10.2174/1381612825666190408122557
  41. Zhu JH, 2021, J CLIN ENDOCR METAB, V106, pE2547, DOI 10.1210/clinem/dgab200
  42. Zhu YY, 2011, ARTHRITIS RHEUM-US, V63, P3136, DOI 10.1002/art.30520

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03